Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Matikas, A; Möbus, V; Greil, R; Andersson, A; Steger, GG; Untch, M; Fornander, T; Malmström, P; Schmatloch, S; Johansson, H; Hellström, M; Brandberg, Y; Gnant, M; Loibl, S; Foukakis, T; Bergh, J, , SweBCG, ABCSG, and, GBG.
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.
J Clin Oncol. 2024; 42(26):3077-3082
Doi: 10.1200/JCO.24.00178
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Study Group Members Med Uni Graz:
- Bauernhofer Thomas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Although dose-dense adjuvant chemotherapy administered once every 2 weeks leads to superior outcomes compared with standard regimens once every 3 weeks, the observed improvement is largely limited to studies using the suboptimal paclitaxel schedule once every 3 weeks as control. PANTHER is an international phase III trial which compared sequential epirubicin/cyclophosphamide and docetaxel administered either once every 2 or once every 3 weeks, with tailored dosing at the dose-dense schedule according to hematologic toxicity. In this end-of-study analysis, the median follow-up was 10.3 years. Compared with standard adjuvant chemotherapy, dose-dense treatment improved breast cancer recurrence-free survival (hazard ratio [HR], 0.80 [95% CI, 0.65 to 0.98]; P = .030), event-free survival (HR, 0.78 [95% CI, 0.65 to 0.94]; P = .009), and distant disease-free survival (HR, 0.79 [95% CI, 0.64 to 0.98]; P = .030) while the improvement in overall survival was not statistically significant (HR, 0.82 [95% CI, 0.65 to 1.04]; P = .109). To our knowledge, this is the first trial that confirms the benefit of a dose-dense regimen over a control regimen containing docetaxel once every 3 weeks.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Breast Neoplasms - drug therapy, pathology, mortality
- Female - administration & dosage
- Chemotherapy, Adjuvant - administration & dosage
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use, adverse effects, administration & dosage
- Cyclophosphamide - administration & dosage, adverse effects
- Docetaxel - administration & dosage
- Epirubicin - administration & dosage
- Middle Aged - administration & dosage
- Adult - administration & dosage
- Aged - administration & dosage
- Drug Administration Schedule - administration & dosage
- Disease-Free Survival - administration & dosage